Biokin’s new cancer drug secures historic approval in China, but Western regulatory hurdles loom
Backed by an $8.4 billion international licensing deal with Bristol Myers Squibb, Biokin’s groundbreaking dual-target therapy…
Early Shanghai trial data points to promise for therapeutic mRNA cancer vaccines
By Da Cheung The American Society of Clinical Oncology (ASCO) annual meeting, which concluded on June…
Beyond Neuralink: China’s BCI industry shatters funding records as government backs brain-computer interfaces
By Da Cheung Chinese companies developing brain-computer interface (BCI) systems are witnessing a surge in fundraising this…
Tiny tech, huge impact: how micro six-axis sensors are giving robots a human touch
By Da Cheung For years, modern imaging and robotics have been giving machines an ever-clearer view…
From Everest to Walmart: exoskeleton startup Hypershell secures over $50 million in fresh funding
By Da Cheung Exoskeletons — once clunky medical devices restricted to rehabilitation centers or science fiction…
Chinese innovative drug makers step onto the global stage through licensing and foreign co-co deals
By Da Cheung In 2025, China’s innovative pharmaceutical companies quietly crossed a historic threshold, overtaking the…
How tech giant Huawei is helping China’s hospitals develop unified AI operating systems
By Lin Jianlan Inside the gleaming atrium of Nanfang Hospital in Guangzhou, an experiment is underway…
China’s AI drug-discovery champion sees survival as the biggest challenge
By Chen Guangjing Do China’s AI drug discovery champions need to worry about survival? For Wen…
Eli Lilly bets $2.75 billion on Insilico Medicine: is this AI drug discovery’s ‘GPT moment’?
By Hualin Wuwang Another traditional industry has officially fallen for AI. On March 29, US pharmaceutical…
Biotech startup METiS Therapeutics plans Hong Kong IPO with AI-driven drug delivery revolution
By Da Cheung METiS Therapeutics, a drug discovery and delivery biotech, has received the regulatory green light…
Latest
- Han’s CNC rides AI infrastructure boom, but expansion brings new risks
- China demonstrates novel net-catch rocket recovery system as it races to close the gap with SpaceX
- China turns to molten salt to tackle renewable energy storage bottlenecks in the national grid
- Dramatic slowdown in China’s range-extended electric vehicle market raises concerns over Xiaomi’s strategy
- Biokin’s new cancer drug secures historic approval in China, but Western regulatory hurdles loom
